Metabolic reprogramming is involved in the pathogenesis of not only cancers but also
neurodegenerative diseases, cardiovascular diseases, and infectious diseases. With the …

Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …

Epigenetic dysregulation is increasingly appreciated as a hallmark of cancer, including
disease initiation, maintenance and therapy resistance. As a result, there have been …

The histone acetyltransferases CBP and p300, often referred to as CBP/p300 due to their
sequence homology and functional overlap and co-operation, are emerging as critical …

CCS1477 (inobrodib) is a potent, selective EP300/CBP bromodomain inhibitor which
induces cell-cycle arrest and differentiation in hematologic malignancy model systems. In …

Epigenetics governs a chromatin state regulatory system through five key mechanisms: DNA
modification, histone modification, RNA modification, chromatin remodeling, and non-coding …

Tumor mutational burden and heterogeneity has been suggested to fuel resistance to many
targeted therapies. The cytosine deaminase APOBEC proteins have been implicated in the …

CBP/p300 proteins are key epigenetic regulators and promising targets for the treatment of
castration-resistant prostate cancer and other types of human cancers. Herein, we report the …

Owing to the development of multiple novel therapies, there has been major progress in the
treatment of advanced prostate cancer over the last two decades; however, the disease …

Lysine acetyltransferases (KATs) are a family of epigenetic enzymes involved in the
regulation of gene expression; they represent a promising class of emerging drug targets …